PT Couch in Crisis Meet the Bloggers

September 24, 2011

Article

Knoll, Pies, Moffic, Blumenfield

Read more about James L. Knoll, IV, MD

Read more aboutRonald Pies, MD

Read more aboutH. Steven Moffic, MD

Read more aboutMichael Blumenfield, MD

Related Videos

Related Content

Psychiatry in the News: September 2023

September 29th 2023

Lifestyle Interventions for ADHD

We Lived Happily During the War

September 29th 2023

Here's to a Psychedelic Revolution

FDA Approves First Oral Selective 5HT1A Receptor Agonist for MDD

September 29th 2023

NDA Submitted for Investigational Muscarinic Antipsychotic in the Treatment of Schizophrenia

September 28th 2023

Psychiatry in the News: September 2023

September 29th 2023

Lifestyle Interventions for ADHD

We Lived Happily During the War

September 29th 2023

Here's to a Psychedelic Revolution

FDA Approves First Oral Selective 5HT1A Receptor Agonist for MDD

September 29th 2023

NDA Submitted for Investigational Muscarinic Antipsychotic in the Treatment of Schizophrenia

September 28th 2023

Psychiatry in the News: September 2023

September 29th 2023

Lifestyle Interventions for ADHD

We Lived Happily During the War

September 29th 2023

Here's to a Psychedelic Revolution

FDA Approves First Oral Selective 5HT1A Receptor Agonist for MDD

September 29th 2023

NDA Submitted for Investigational Muscarinic Antipsychotic in the Treatment of Schizophrenia

September 28th 2023

Related Content

Here are some updates from the world of psychiatry throughout the month of September.

Psychiatry in the News: September 2023

September 29th 2023

Lifestyle Interventions for ADHD

Lifestyle Interventions for ADHD

war torn hosue

We Lived Happily During the War

September 29th 2023

Here's to a Psychedelic Revolution

Here's to a Psychedelic Revolution

Urupong/Adobestock Brain Depression Breakthrough

FDA Approves First Oral Selective 5HT1A Receptor Agonist for MDD

September 29th 2023

The treatment, if approved, “will represent the first novel pharmacological approach to treating schizophrenia in several decades and provide a new treatment option for patients and their physicians.”

NDA Submitted for Investigational Muscarinic Antipsychotic in the Treatment of Schizophrenia

September 28th 2023

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.